Beam Therapeutics Inc. saw its stock price soar 5.23% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.
The surge appears to be driven by positive analyst actions, with Clear Street reaffirming its Buy rating on the stock and setting a price target of $37.00, while Wedbush raised its price target on Beam Therapeutics from $57 to $65.
These analyst upgrades and reaffirmations have likely boosted investor confidence in the company's prospects, contributing to the strong buying activity during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.